IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 10,000 Shares of Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 10,000 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was purchased at an average cost of $1.09 per share, with a total value of $10,900.00. Following the completion of the acquisition, the insider directly owned 762,103 shares of the company’s stock, valued at approximately $830,692.27. The trade was a 1.33% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Stock Performance

Shares of NASDAQ IRIX opened at $0.88 on Thursday. The firm’s 50 day moving average price is $0.73 and its 200-day moving average price is $0.95. IRIDEX Corporation has a 52-week low of $0.61 and a 52-week high of $1.65. The company has a market cap of $15.46 million, a PE ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The company had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. On average, analysts forecast that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Institutional Trading of IRIDEX

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new stake in IRIDEX during the second quarter valued at approximately $29,000. Diversify Advisory Services LLC bought a new position in IRIDEX in the second quarter worth approximately $30,000. Diversify Wealth Management LLC purchased a new position in shares of IRIDEX during the 1st quarter worth $35,000. United Capital Financial Advisors LLC purchased a new position in shares of IRIDEX during the 2nd quarter worth $41,000. Finally, Thompson Davis & CO. Inc. grew its position in shares of IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the period. 20.10% of the stock is currently owned by institutional investors.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.